{"preliminary_commentary":{"by_channel":{"x_thread":16},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03834519\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["pembrolizumab","olaparib"]],"indication":"previously treated metastatic castration-resistant prostate cancer","name":"KEYLYNK-010","nct_id":"NCT03834519","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keylynk-010-nct03834519. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"KEYLYNK-010","arms":[{"description":"Participants will receive olaparib 600 mg as two 150 mg oral tablets twice daily (BID) continuously until progression PLUS on Day 1 of each 21-day cycle, pembrolizumab 200 mg by intravenous (IV) infusion for up to 35 cycles (approximately 2 years).","label":"Pembrolizumab + Olaparib","type":"EXPERIMENTAL"},{"description":"Participants will receive a single NHA, which will be either abiraterone acetate (participants previously treated with enzalutamide) 1000 mg as two 500 mg or four 250 mg oral tablets once daily (QD) PLUS prednisone or prednisolone 10 mg as one 5 mg tablet BID until progression OR enzalutamide (participants previously treated with abiraterone acetate) 160 mg as four 40 mg oral tablets or capsules OR two 80 mg tablets QD until progression.","label":"Next-generation Hormonal Agent Monotherapy (NHA)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-01-27","type":"ACTUAL"},"conditions":["Prostatic Neoplasms"],"enrollment":{"count":793,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Olaparib","otherNames":["MK-7339","AZD-2281","LYNPARZA®"],"type":"DRUG"},{"name":"Abiraterone acetate","otherNames":["ZYTIGA®","CB-7630","JNJ-212082"],"type":"DRUG"},{"name":"Prednisone","otherNames":[],"type":"DRUG"},{"name":"Enzalutamide","otherNames":["XTANDI®","MDV-3100","ASP-9785"],"type":"DRUG"},{"name":"Prednisolone","otherNames":[],"type":"DRUG"}],"last_update":"2025-05-18","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-03-14","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to ~31 months"},{"measure":"Radiographic Progression-Free Survival (rPFS)","timeFrame":"Up to ~26 months"}],"references":[{"citation":"Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, McDermott R, Sala-Gonzalez N, Fong PC, Greil R, Retz M, Sade JP, Yanez P, Huang YH, Begbie SD, Gafanov RA, De Santis M, Rosenbaum E, Kolinsky MP, Rey F, Chiu KY, Roubaud G, Kramer G, Sumitomo M, Massari F, Suzuki H, Qiu P, Zhang J, Kim J, Poehlein CH, Yu EY. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol. 2023 Aug 1;41(22):3839-3850. doi: 10.1200/JCO.23.00233. Epub 2023 Jun 8.","pmid":"37290035","type":"RESULT"},{"citation":"Mehra N, Antonarakis ES, Park SH, Goh JC, McDermott R, Sala Gonzalez N, Fong PC, Greil R, De Santis M, Yanez PE, Huang YH, Begbie SD, Rey F, Kramer G, Suzuki H, Saretsky TL, Ghate SR, Cui Y, Hosius C, Yu EY. Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2025 Aug;8(4):1030-1040. doi: 10.1016/j.euo.2025.04.018. Epub 2025 Jul 19.","pmid":"40685311","type":"DERIVED"}],"start_date":{"date":"2019-05-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)","url":"https://clinicaltrials.gov/study/NCT03834519"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keylynk-010-nct03834519"}